Lung large cell carcinoma

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This phase 2 pilot trial tested adding the drug bevacizumab to standard chemotherapy and radiation for patients with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 29 newly diagnosed patients to see if the combination is safe and helps …

This study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…

This study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation therapy helps prevent lung cancer from coming back in people with early-stage non-small cell lung cancer. About 140 participants will receive either radiation alone or radiation plus…

This early-phase trial planned to test a new approach for people with metastatic non-small cell lung cancer. Doctors would remove immune cells from the tumor, edit them with CRISPR to remove a gene called CISH, and then infuse them back to help fight the cancer. However, the tria…

This trial is testing a new way to give radiation therapy for people with stage II-III non-small cell lung cancer that cannot be removed with surgery. Instead of standard daily radiation for many weeks, patients receive a shorter, higher-dose course (hypofractionated radiation) a…

This study is collecting blood samples from 102 patients with non-small cell lung cancer, colorectal cancer, or pancreatic cancer who are receiving standard treatments. Researchers will analyze the blood for cancer DNA (ctDNA) to see how it changes over time and whether it relate…